The upper arm site refers specifically to the upper arm (subcutaneous fat over the triceps area) , where there is adequate subcutaneous fat, rather than the forearm or other areas with insufficient fatty tissue
Our findings suggest that a randomised controlled trial of GLP-1 receptor agonist use in people with diabetes and depression, anxiety, or both would be worthwhile. Professor Mark Taylor from Griffith University, and one of the studys authors, said: An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder
Specifically, the FDA states that microdosing is not a regulated term and there is no clinical evidence from large-scale trials demonstrating the safety and effectiveness of GLP-1 microdosing for mild appetite control, weight management, or longevity
Clinical trials studying the effects of GLP-1 and GIP agonists have shown great results
If a product has a shelf life that keeps it intact long after its made, its probably not a great thing for the body
"It's probably one of the most popular drug classes we've seen." Jensen urges patients to avoid compounded versions altogether, as you can't guarantee purity or safety
